Monitor the full Q3 earnings call on Nov 12 for details on sales force stabilization and corrective actions. The guidance suspension and flat revenue with declining core tissue volumes suggest downside risk to consensus estimates for Q4 and FY2027.
Price Chart
Executive Summary
mdxhealth pre-announced Q3 2026 revenue of ~$22.7M (flat YoY), suspended its full-year 2026 revenue guidance of $110-115M, and cited unexpected sales force turnover. Tissue-based test volumes fell 11% YoY, while liquid-based volumes grew 156% YoY from the September 2025 acquisition. The EPS miss in the prior quarter (-95.7% vs consensus) and the guidance suspension signal worsening operational challenges.
Key Financial Metrics
Key Facts
- Q3 2026 preliminary revenue ~$22.7M, flat vs $22.7M in Q3 2025 (re-presented)
- Full-year 2026 revenue guidance of $110-115M suspended
- Tissue-based test volume (Confirm mdx, GPS mdx) 11,232, down 11% YoY
- Liquid-based test volume (Exo mdx) 11,792 vs 4,600 in prior-year period (includes Select mdx and Exo mdx from Sept 2025 acquisition)
- Cash and equivalents ~$31.7M as of Sept 30, 2026
- Prior quarter (Q2 2026) EPS of $-0.18 missed consensus of $-0.09 by -95.7%
Financial Impact
Revenue flat at ~$22.7M; guidance suspension removes $110-115M full-year target; cash burn continues with $31.7M remaining
Risk Factors
- Sales force turnover may persist, further depressing test volumes
- Cash runway limited to ~$31.7M with no profitability in sight
- Full-year guidance suspension signals lack of visibility into recovery timeline
- Competitive recruiting pressure could continue to disrupt sales execution
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3382098 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | 6-K | $0.2070 $0.1830 | ▲ +11.59% | ▲ +11.69% | $0.1830 (+11.59%) |
Oct 15, 2026 11d ago | SC 13D/A | $0.2066 $0.1833 | ▲ +11.28% | ▲ +10.85% | $0.1830 (+11.42%) |
Oct 15, 2026 11d ago | Press Release | $0.2066 $0.1833 | ▲ +11.28% | ▲ +10.85% | $0.1830 (+11.42%) |
Sep 17, 2026 5w ago | 144 | $0.6300 $0.5650 | ▲ +10.32% | ▲ +11.59% | $0.1830 (+70.95%) |
Sep 3, 2026 7w ago | 6-K | $0.7484 $0.7072 | ▲ +5.51% | ▲ +4.30% | $0.1830 (+75.55%) |
Aug 13, 2026 10w ago | 6-K | $0.8080 $0.7431 | ▲ +8.03% | ▲ +6.66% | $0.1830 (+77.35%) |
Aug 13, 2026 10w ago | Press Release | $0.8080 $0.7431 | ▼ −8.03% | ▼ −6.66% | $0.1830 (−77.35%) |
Jul 24, 2026 13w ago | 6-K | $0.4180 $0.4180 | · 0.00% | ▲ +1.07% | $0.1830 (+56.22%) |
Jul 2, 2026 16w ago | Press Release | $0.4765 $0.4899 | ▼ −2.81% | ▼ −1.88% | $0.1830 (+61.59%) |
Apr 29, 2026 25w ago | 6-K | $2.04 $2.01 | ▼ −1.47% | ▼ −3.20% | $0.1830 (−91.03%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers